KN069 Research Reference

Catalog classification, reference sizes, lab math links, and source-backed data. Educational use only — not medical advice.

Researched for: PepTools vendor-neutral scientific reference catalog

Investigational biologic; GLP-1 receptor agonist and GIP receptor antagonist fusion protein compound Reference needs_revision Best effort · source review pending

Also known as: KN-069, KN069 injection

Open in Calculator ← Compound Index All Tools

Best-effort research profile: this record has not passed full two-source scientific verification. Descriptive fields, research protocols, storage/handling notes, and interaction guidance below are shown with their evidence labels, but calculator presets and exact dosing math remain hidden until the record is verified or reaches Community-Supported status.

Quick Facts

Reference Sizes

Not standardized / source review pending

Best-Effort Research Profile

KN069 is an investigational protein therapeutic under phase 1 clinical evaluation in adults with overweight or obesity. Published clinical data describe dual GLP-1R agonism and GIPR antagonism, with pharmacokinetic, pharmacodynamic, safety, and immunogenicity assessments conducted after subcutaneous administration.

Source review pending. This descriptive profile is shown from the available source material as a best-effort educational reference. It has not passed the full verification bar and is not a dosing instruction, medical claim, or treatment recommendation.

Research Profile

Half-Life

Total KN069 half-life reported as 899.74–1099.01 hours in a phase 1 study; the measured parameter was total KN069, not necessarily intact active drug.

Administration Routes (Research)

subcutaneous injection

Reported Research Effects

GLP-1 receptor agonist activity
GIP receptor antagonist activity
Dose-proportional exposure reported over 12–90 mg in a phase 1 study
Long terminal half-life reported for total KN069
Preliminary dose-dependent body-weight reductions reported in the phase 1 study
Predominantly mild-to-moderate gastrointestinal adverse events reported in the phase 1 study

Data source: Primary literature, regulator records, trial registries, and identity-specific evidence search

Reflects preclinical/research literature context only. Not a medical claim, dosing instruction, or treatment recommendation.

Research Notes

Phase 1 first-in-human research included a randomized, double-blind, placebo-controlled single-ascending-dose study of 12–120 mg and a multiple-ascending-dose study with dose escalation from 15–60 mg in Chinese male participants with overweight or obesity. Pharmacokinetics were assessed for intact and total KN069 by sandwich ELISA. The record is retained as researching because common reference sizes, molecular composition, formulation, storage requirements, solubility, and onset data were not reliably established from authoritative public sources.

Supplementary research context only. Not medical advice or a treatment recommendation.

Registry Identifiers

ClinicalTrials.gov: NCT06547775; PubMed: PMID 42010360; DOI: 10.1111/dom.70794

Source-Backed Observations

The compound is not represented as a conventional small-molecule chemical entity in the authoritative sources reviewed. No reliable public molecular formula, amino-acid sequence, CAS Registry Number, molecular mass, or detailed formulation information was identified. Clinical-trial evidence describes single ascending doses of 12–120 mg and multiple ascending doses of 15–60 mg; these are study regimens rather than catalog pack sizes.

Reflects published research. Educational reference — not a recommendation for use.

Sources Under Review

A Phase 1, Randomised, Double-Blind, Placebo-Controlled Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of KN069 (a Dual GLP-1R Agonist and GIPR Antagonist) in Male Adults With Overweight or Obesity
https://pubmed.ncbi.nlm.nih.gov/42010360/ (accessed 2026-09-12)

A Phase 1, Randomised, Double-Blind, Placebo-Controlled Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of KN069 (a Dual GLP-1R Agonist and GIPR Antagonist) in Male Adults With Overweight or Obesity
https://dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.70794 (accessed 2026-09-12)

Suggest a community source

Found a relevant Reddit or forum thread about this compound? Suggest it below. Every suggestion is reviewed by an editor before it appears -- nothing is published automatically.

Related Research Tools

Reconstitution CalculatorConcentration, draw volume, per-unit amounts Unit Convertermg, mcg, mL, units conversion Compound CompareSide-by-side comparison tool Cost CalculatorCost per mg, mcg, per-draw

Research Use Only. All content is for educational and research reference only. Not medical advice, a treatment recommendation, or guidance on human use. Compounds are not FDA-approved drugs unless specifically noted.